UPMC Hillman Cancer Center

Edward Chu, MD

Edward Chu
Deputy Director, UPMC Hillman Cancer Center
Co-Leader, Hillman Cancer Therapeutics Program
Chief, Division of Hematology/Oncology
Stanley M. Marks, MD-OHA Chair in Hematology/Oncology Leadership
Professor of Medicine, Pharmacology & Chemical Biology, and Clinical and Translational Science

Contact Information

Contact Information

5150 Centre Avenue
Fifth Floor, Room 571
Pittsburgh, PA 15232

Email: chue2@upmc.edu

Administrative Assistant
Name: Lois Malehorn
Phone: 412-648-6589
Email: malehornlm@upmc.edu
Fax: 412-648-6579

Research Keywords

Research Keywords

Colorectal cancer; cancer drug development; drug resistance; Chinese herbal medicine; early phase clinical trials

Research Summary

Research Summary

Dr. Edward Chu is involved in basic, clinical, and translational cancer research. His basic research interests are focused on the characterization of molecular mechanisms underlying the development of cellular drug resistance, especially as it relates to the fluoropyrimidine class of anticancer agents. His research group was the first to identify translational autoregulation as a novel regulatory mechanism in eukaryotes for controlling the expression of the folate-dependent enzymes, thymidylate synthase and dihydrofolate reductase. His clinical/translational research efforts focus on identifying novel drugs and treatment strategies for colorectal cancer and other GI cancers and in developing early phase clinical trials. He has a strong interest in integrating Chinese herbal medicine with standard cancer chemotherapy, with the goal of enhancing clinical activity and reducing toxicities.

Selected Publications

Selected Publications

  • Lee JJ and Chu E. Sequencing of anti-angiogenic agents in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2014 Sep;13(3):135-44. PubMed Link
  • Vater LB, Donohue JM, Arnold R, White DB, Chu E, Schenker Y. What are cancer centers advertising to the public?: a content analysis. Ann Intern Med. 2014 Jun 17;160(12):813-20. PubMed Link
  • Parikh RA, Wang P, Beumer JH, Chu E, Appleman LJ. The potential role of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. Onco Targets Ther. 2014 Jun 11;7:969-83. PubMed Link
  • Wei N, Chu E, Wipf P, Schmitz JC. Protein kinase D as a potential chemotherapeutic target for colorectal cancer. Mol Cancer Ther. 2014 May;13(5):1130-41. PubMed Link
  • Liu H, Schmitz JC, Wei J, Cao S, Beumer JH, Strychor S, Cheng L, Liu M, Wang C, Chu E, Lin X. Clove extract inhibits tumor growth and promotes cell cycle arrest and apoptosis. Oncol Res. 2014;21(5):247-59. PubMed Link
  • Wu SY, Chen TM, Gmeiner WH, Chu E, Schmitz JC. Development of modified siRNA molecules incorporating 5-fluoro-2-prime-deoxyuridine residues to enhance cytotoxicity. Nucleic Acids Res. 2013 Apr;41(8):4650-9. PubMed Link
  • Beumer JH, Chu E, Salamone SJ. Body-surface area-based chemotherapy dosing: appropriate in the 21st century? J Clin Oncol. 2012 Nov 1;30(31):3896-7. PubMed Link
  • Chu E. An update on the current and emerging trends in metastatic colorectal cancer. Clin Colorectal Cancer. 2012 Mar;11(1):1-13. PubMed Link
  • Schmitz JC and Chu E. Effect of small interfering RNA 3-prime-end overhangs on chemosensitivity to thymidylate synthase inhibitors. Silence. 2011 Jan 19;2(1):1. PubMed Link
  • Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically-guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst. 2009 Nov 18;101(22):1543-52. PubMed Link

See all pubs (Pubmed)

Collaborations

Collaborations

Current Internal Collaborators

Leonard Appleman, MD, PhD
Associate Professor of Medicine
Member - Cancer Therapeutics Program (CTP)

Robert Arnold, MD
Professor of Medicine and Leo H. Creip Chair of Patient Care

Christopher Bakkenist, PhD
Associate Professor of Radiation Oncology
Member - Molecular and Cellular Cancer Biology Program (MCCBP)

Jan-Hendrik Beumer, PharmD, PhD
Associate Professor of Pharmaceutical Sciences
Member - Cancer Therapeutics Program (CTP)

Julie Eiseman, PhD
Professor of Pharmacology & Chemical Biology
Member - Cancer Therapeutics Program (CTP)

James Lee, MD, PhD
Associate Professor of Medicine
Member - Cancer Therapeutics Program (CTP)

Yael Schenker, MD
Assistant Professor of Medicine
Member - Biobehavioral Oncology Program (BOP)

John Schmitz, PhD
Associate Professor of Medicine
Member - Cancer Therapeutics Program (CTP)

Peter Wipf, PhD
Distinguished University Professor of Chemistry
Co-Leader - Cancer Therapeutics Program (CTP)

Current External Collaborators

Yung-Chi Cheng, PhD
Henry Bronson Professor of Pharmacology
Yale University

Howard Hochster, MD
Professor of Medicine
Yale University

Tae-Won Kim, MD, PhD
Professor of Medicine
Asan Medical Center, Seoul, South Korea

KP Kim, MD, PhD
Assistant Professor of Medicine
Asan Medical Center, Seoul, South Korea

Yun Yen, MD, PhD
Associate Director for Translational Research; Chair and Professor of Molecular Pharmacology
City of Hope

Shared Resource Usage

Shared Resource Usage

  • Animal Facility
  • Biostatistics Facility
  • Cancer Bioinformatics Services
  • Cancer Genomics Facility
  • Cancer Pharmacokinetics and Pharmacodynamics Facility
  • Cancer Proteomics Facility
  • Chemical Biology Facility
  • IMCPL
  • In Vivo Imaging Facility
  • Investigational Drug Services
  • Tissue and Research Pathology Services

Affiliated Graduate Programs

Affiliated Graduate Programs

  • Molecular Pharmacology

Department Website









Last modified: 12/4/17